Abstract

Clinically used heart valve prostheses, despite their progress, are still associated with limitations. Biodegradable poly-ε-caprolactone (PCL) nanofiber scaffolds, as a matrix, were seeded with human endothelial colony-forming cells (ECFCs) and human induced-pluripotent stem cells-derived MSCs (iMSCs) for the generation of tissue-engineered heart valves. Cell adhesion, proliferation, and distribution, as well as the effects of coating PCL nanofibers, were analyzed by fluorescence microscopy and SEM. Mechanical properties of seeded PCL scaffolds were investigated under uniaxial loading. iPSCs were used to differentiate into iMSCs via mesoderm. The obtained iMSCs exhibited a comparable phenotype and surface marker expression to adult human MSCs and were capable of multilineage differentiation. EFCFs and MSCs showed good adhesion and distribution on PCL fibers, forming a closed cell cover. Coating of the fibers resulted in an increased cell number only at an early time point; from day 7 of colonization, there was no difference between cell numbers on coated and uncoated PCL fibers. The mechanical properties of PCL scaffolds under uniaxial loading were compared with native porcine pulmonary valve leaflets. The Young’s modulus and mean elongation at Fmax of unseeded PCL scaffolds were comparable to those of native leaflets (p = ns.). Colonization of PCL scaffolds with human ECFCs or iMSCs did not alter these properties (p = ns.). However, the native heart valves exhibited a maximum tensile stress at a force of 1.2 ± 0.5 N, whereas it was lower in the unseeded PCL scaffolds (0.6 ± 0.0 N, p < 0.05). A closed cell layer on PCL tissues did not change the values of Fmax (ECFCs: 0.6 ± 0.1 N; iMSCs: 0.7 ± 0.1 N). Here, a successful two-phase protocol, based on the timed use of differentiation factors for efficient differentiation of human iPSCs into iMSCs, was developed. Furthermore, we demonstrated the successful colonization of a biodegradable PCL nanofiber matrix with human ECFCs and iMSCs suitable for the generation of tissue-engineered heart valves. A closed cell cover was already evident after 14 days for ECFCs and 21 days for MSCs. The PCL tissue did not show major mechanical differences compared to native heart valves, which was not altered by short-term surface colonization with human cells in the absence of an extracellular matrix.

Highlights

  • Tissue engineering offers a unique opportunity by providing a living valve that is capable of growth and biological integration [1]

  • A successful two-phase protocol based on the timed use of differentiation factors for efficient differentiation of iPSCs into induced-pluripotent stem cells-derived MSCs (iMSCs) has been developed

  • A successful two-phase protocol based on the timed use of differentiation factors for efficient differentiation of human iPSCs into iMSCs was developed: cells were generated using a novel feeder-free differentiation protocol in a fast manner

Read more

Summary

Introduction

Tissue engineering offers a unique opportunity by providing a living valve that is capable of growth and biological integration [1]. Despite the enormous progress made in the development of tissue-engineered heart valves, a clinically relevant and commonly used product has not yet been realized. Leaflets of native human heart valves with their orthotropic nature consist of proteoglycans, highly organized collagen network, elastin fibers (ECM), and valve interstitial cells (VIC). They are surrounded by an outer layer of specialized endothelial cells (valvular endothelial cells = VEC). The adult endothelial progenitor cells used in cardiovascular research originate from the bone marrow, circulate in the peripheral blood, and contribute to neovascularization [2]. These so-called endothelial colony forming cells (ECFCs) are isolated from the blood [3] and are suitable for therapeutic use [4,5]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call